Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17525 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von María José Casanova und 41 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónom…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained ADA originator vs. those who switched to ADA biosimilar.
Methods
Patients receiving ADA originator who were in clinical remission at standard dose of ADA originator were included. Patients who maintained ADA originator formed the non‐switch cohort (NSC), and those who switched to different ADA biosimilars constituted the switch cohort (SC). Clinical remission was defined as a Harvey–Bradshaw index ≤4 in Crohn's disease and a partial Mayo score ≤2 in ulcerative colitis. To control possible confounding effects on treatment discontinuation, an inverse probability treatment weighted proportional hazard Cox regression was performed.
Results
Five hundred and twenty‐four patients were included: 211 in the SC and 313 in the NSC. The median follow‐up was 13 months in the SC and 24 months in the NSC ( p < 0.001). The incidence rate of ADA discontinuation was 8% and 7% per patient‐year in the SC and in the NSC, respectively ( p > 0.05). In the multivariate analysis, switching from ADA originator to ADA biosimilar was not associated with therapy discontinuation. The incidence rate of relapse was 8% per patient‐year in the SC and 6% per patient‐year in the NSC ( p > 0.05). Six percent of the patients had adverse events in the SC vs. 5% in the NSC ( p > 0.05).
Conclusion
Switching to ADA biosimilar did not impair patients' outcomes in comparison with maintaining on the originator.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enferme…
- Gastroenterology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
- Gastroenterology Department, Hospital Universitario de Cabueñes, Gijón, Spain.
- Gastroenterology Department, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain.
- Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain.
- Gastroenterology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
ORCID-Profile: María José Casanova, Margalida Calafat, José María Huguet, Alejo Mancebo, Francisco Mesonero, Beatriz Gros, María Chaparro, Javier P Gisbert
Zitieren
APA
Casanova, M. J., Nantes, Ó., Varela, P., Vela-González, M., Rivero, M., Sierra-Gabarda, O., Riestra, S., Barreiro-de Acosta, M., Martín-Rodríguez, M. D. M., Gargallo-Puyuelo, C. J., Reygosa, C., Muñoz, R., de la Filia-Molina, I. G., Núñez-Ortiz, A., Kolle, L., Calafat, M., Huguet, J. M., Iglesias-Flores, E., Martínez-Pérez, T. J., …, & Gisbert, J. P. (2023). Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17525
Vancouver
Casanova MJ, Nantes Ó, Varela P, Vela-González M, Rivero M, Sierra-Gabarda O, et al. Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17525
BibTeX
@article{Casanova2023,
author = {Casanova, María José and Nantes, Óscar and Varela, Pilar and Vela-González, Milagros and Rivero, Montserrat and Sierra-Gabarda, Olivia and Riestra, Sabino and Barreiro-de Acosta, Manuel and Martín-Rodríguez, María Del Mar and Gargallo-Puyuelo, Carla Jerusalén and Reygosa, Cristina and Muñoz, Roser and de la Filia-Molina, Irene García and Núñez-Ortiz, Andrea and Kolle, Lilyan and Calafat, Margalida and Huguet, José María and Iglesias-Flores, Eva and Martínez-Pérez, Teresa de Jesús and Bosch, Orencio and Duque-Alcorta, José María and Frago-Larramona, Santiago and Van Domselaar, Manuel and González-Cosano, Víctor Manuel and Bujanda, Luis and Rubio, Saioa and Mancebo, Alejo and Castro, Beatriz and García-López, Santiago and de Francisco, Ruth and Nieto-García, Laura and Laredo, Viviana and Gutiérrez-Casbas, Ana and Mesonero, Francisco and Leo-Carnerero, Eduardo and Cañete, Fiorella and Ruiz, Lucía and Gros, Beatriz and Del Moral-Martínez, María and Rodríguez, Cristina and Chaparro, María and Gisbert, Javier P},
title = {Real‐world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA‐SWITCH study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17525}
}
EUVIMED